{"id":"NCT02933866","sponsor":"Sun Pharmaceutical Industries, Inc.","briefTitle":"Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis","officialTitle":"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS Topical Product in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-11","primaryCompletion":"2016-11-16","completion":"2017-09-29","firstPosted":"2016-10-14","resultsPosted":"2018-12-06","lastUpdate":"2018-12-06"},"enrollment":371,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Scalp Psoriasis"],"interventions":[{"type":"DRUG","name":"DSXS topical","otherNames":["Active"]},{"type":"DRUG","name":"Vehicle topical","otherNames":["placebo"]}],"arms":[{"label":"DSXS topical","type":"EXPERIMENTAL"},{"label":"Vehicle topical","type":"PLACEBO_COMPARATOR"}],"summary":"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis","primaryOutcome":{"measure":"Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success","timeFrame":"Day 29","effectByArm":[{"arm":"DSXS Topical","deltaMin":49,"sd":null},{"arm":"Vehicle Topical","deltaMin":41,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2961"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":183},"commonTop":["Headache","Eye irritation","Application site pain","Application site pruritus","Nasopharyngitis"]}}